These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 30088720)
1. Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study. Mattiolli AB; Santos A; Vicente A; Queiroz M; Bastos D; Herchenhorn D; Srougi M; Peixoto FA; Morikawa L; da Silva JLF; Etchebehere E Int Braz J Urol; 2018; 44(5):892-899. PubMed ID: 30088720 [TBL] [Abstract][Full Text] [Related]
2. Detection Efficacy of Hybrid Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912 [TBL] [Abstract][Full Text] [Related]
3. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066 [TBL] [Abstract][Full Text] [Related]
6. Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747 [TBL] [Abstract][Full Text] [Related]
7. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244 [TBL] [Abstract][Full Text] [Related]
8. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values. Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016 [TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
10. Correlations between whole body volumetric parameters of Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097 [TBL] [Abstract][Full Text] [Related]
11. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731 [TBL] [Abstract][Full Text] [Related]
12. Preliminary results of a Rousseau C; Le Thiec M; Ferrer L; Rusu D; Rauscher A; Maucherat B; Frindel M; Baumgartner P; Fleury V; Denis A; Morel A; Varmenot N; Debeaupuis E; Campion L; Kraeber-Bodéré F Prostate; 2019 Sep; 79(13):1514-1522. PubMed ID: 31421657 [TBL] [Abstract][Full Text] [Related]
13. Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716 [TBL] [Abstract][Full Text] [Related]
14. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121 [TBL] [Abstract][Full Text] [Related]
15. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335 [TBL] [Abstract][Full Text] [Related]
17. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589 [TBL] [Abstract][Full Text] [Related]
18. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Okudan B; Coşkun N; Seven B; Atalay MA; Yildirim A; Görtan FA Nucl Med Commun; 2021 Nov; 42(11):1254-1260. PubMed ID: 34284438 [TBL] [Abstract][Full Text] [Related]
19. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological predictors of positive Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]